SADDLE BROOK, N.J.& AACHEN, Germany--(BUSINESS WIRE)--CircuLite®, Inc. today announced that the latest data from patients enrolled in the Company’s CE Mark trial of the SYNERGY® Circulatory Support System were presented on Monday, September 10 in a “Late-breaking News” podium presentation at the Heart Failure Society of America Annual Scientific Meeting. The presented data focused on results from the most recently implanted patients who received the optimized version of the system. Results from these patients strengthened prior findings indicating that implantation with SYNERGY resulted in significant, sustained improvements in hemodynamics and exercise tolerance. SYNERGY, which recently received CE Mark approval in Europe, is a micro-pump designed to halt the progression of heart failure and to improve symptoms and exercise tolerance. By working with the heart’s native pumping capacity, the SYNERGY System is specifically targeted for treatment of ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA III and early IV) who remain symptomatic despite standard medical management.
